Canada on Monday suspended administering the COVID-19 vaccine by AstraZeneca and Oxford University for people under 55 years of age citing concerns over blood clots reported in Europe.
The suspension was recommended by its National Advisory Committee on Immunization as the vaccine has been associated with blood clotting, a condition that has come to be known as Vaccine-Induced Prothrombotic Immune Thrombocytopenia.
No cases have been reported in Canada, but there have been a handful reported in Europe, primarily among women below the age of 55.
More than a dozen European countries earlier this month temporarily shelved the AstraZeneca vaccine while the European regulator investigated the potential connection between blood clots and the life-saving jab. Governments have since restarted their AstraZeneca vaccine campaigns after the regulator ruled the drug was safe and its benefits outweighed its risks.